Q

Qingdao NovelBeam Technology Co Ltd
SSE:688677

Watchlist Manager
Qingdao NovelBeam Technology Co Ltd
SSE:688677
Watchlist
Price: 100.52 CNY 4.17% Market Closed
Market Cap: ¥12.1B

EV/EBIT

57.1
Current
91%
More Expensive
vs 3-y average of 29.9

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
57.1
=
Enterprise Value
¥7.9B
/
EBIT
¥202.6m

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
57.1
=
Enterprise Value
¥7.9B
/
EBIT
¥202.6m

Valuation Scenarios

Qingdao NovelBeam Technology Co Ltd is trading above its 3-year average

If EV/EBIT returns to its 3-Year Average (29.9), the stock would be worth ¥52.61 (48% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-49%
Maximum Upside
No Upside Scenarios
Average Downside
48%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 57.1 ¥100.52
0%
3-Year Average 29.9 ¥52.61
-48%
5-Year Average 31.1 ¥54.8
-45%
Industry Average 29.4 ¥51.79
-48%
Country Average 28.9 ¥50.89
-49%

Forward EV/EBIT
Today’s price vs future ebit

Today's Enterprise Value EBIT Forward EV/EBIT
¥7.9B
/
Oct 2025
¥202.6m
=
57.1
Current
¥7.9B
/
Dec 2025
¥202m
=
38.9
Forward
¥7.9B
/
Dec 2026
¥245.9m
=
32
Forward
¥7.9B
/
Dec 2027
¥301.5m
=
26.1
Forward

Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
CN
Qingdao NovelBeam Technology Co Ltd
SSE:688677
12.1B CNY 57.1 69.1
US
Intuitive Surgical Inc
NASDAQ:ISRG
171.2B USD 55.9 60
US
Abbott Laboratories
NYSE:ABT
158.3B USD 18.8 25.2
US
Stryker Corp
NYSE:SYK
125.3B USD 23.9 38.6
IE
Medtronic PLC
NYSE:MDT
106.9B USD 18.8 23.2
US
Boston Scientific Corp
NYSE:BSX
92B USD 25.3 31.8
DE
Siemens Healthineers AG
XETRA:SHL
40B EUR 15.1 18.9
US
Edwards Lifesciences Corp
NYSE:EW
48.9B USD 27.2 45.5
US
IDEXX Laboratories Inc
NASDAQ:IDXX
45.1B USD 33.3 42.6
US
Becton Dickinson and Co
NYSE:BDX
43.3B USD 16.6 24.7
US
Resmed Inc
NYSE:RMD
32B USD 16.8 21.6

Market Distribution

Higher than 72% of companies in China
Percentile
72st
Based on 5 337 companies
72st percentile
57.1
Low
0 — 16.6
Typical Range
16.6 — 52.9
High
52.9 —
Distribution Statistics
China
Min 0
30th Percentile 16.6
Median 28.9
70th Percentile 52.9
Max 49 021

Qingdao NovelBeam Technology Co Ltd
Glance View

Market Cap
12.1B CNY
Industry
Health Care

Qingdao NovelBeam Technology Co., Ltd. engages in the research and development of optics technology, the manufacture of optical instruments, and the provision of design solutions for medical, life science, laser, and micro-display projection applications. The company is headquartered in Qingdao, Shandong and currently employs 854 full-time employees. The company went IPO on 2021-02-26. Its main products of medical endoscope equipment include fluorescent endoscopes, fluorescent camera adapters/adaptive lenses, fluorescent light source modules and white light source modules. Its medical endoscopic equipment products are mainly used in abdominal endoscopic surgery such as liver and gallbladder and gastrointestinal surgery. Its optical products mainly include medical optical products, industrial and laser optical products, and biometric products. Among them, the biometric products include fingerprint devices, palmprint devices and related accessories. In addition, the Company also provides technical services and house leasing services. The firm distributes its products both in the domestic market and to overseas markets.

Intrinsic Value
47.77 CNY
Overvaluation 52%
Intrinsic Value
Price ¥100.52
Q
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett